What we do
Founding Assets in Edinburgh
Our interests:
We are interested in talking to potential development partners, collaborators and investors on all programmes. This includes topical and reformulation partners, clinical development partners, pharma partners / investors and senior executives who may which to join.
Our pipeline:
Our pipeline is based new science & clinical insights for more effective drugs in CNS, in the first instance Neuropathic Pain and Cognition, and devices that help assess disease onset and monitor progression.
Our drug pipeline includes discovery, development and clinical stage projects:
- Reformulation to an oral product of an existing drug for Cancer (drug-induced) pain.
- Development of a suite of a GRAS topical and transdermal solutions for peripheral neuropathies
- Drug discovery project on the analgesic and cool receptor TRPM8
- Development of a natural product derived compound for improved cognitive function
Our devices are all based on a stratified approach to medicine that includes patient assesment, selection for trials, and/or better treatment and care.
- Delirium test, a research device for the detection, assessment and monitoring, of delirium.
- AD test, a laptop based test for the early assessment and monitoring of onset of Alzheimer’s disease.
- In collaboration with ‘I’m Able Ltd’., we are also marketing their product, Able-X, aimed at brian to limb function, particularly aimed at stroke rehabilitation
- With our clinical colleagues we are investigating a new non-subjective pain assessment device.